A New Frontier in ADHD Pharmacotherapy: Centanafadine (SIMTRIYO®)

from TheBrief.Health · host TheBrief.Health

The FDA has approved SIMTRIYO®, or centanafadine, for treating ADHD in adults and children six years and older. This is a significant development, as centanafadine is the first norepinephrine, dopamine, and serotonin reuptake inhibitor, or NDSRI, approved for ADHD.

Episode metadata supplied by the publisher feed · Published Aug 11, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

A New Frontier in ADHD Pharmacotherapy: Centanafadine (SIMTRIYO®)

0:00 1:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on August 11, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!